The long quest for neonatal screening for severe combined immunodeficiency - PubMed (original) (raw)

Review

The long quest for neonatal screening for severe combined immunodeficiency

Rebecca H Buckley. J Allergy Clin Immunol. 2012 Mar.

Abstract

Early recognition of severe combined immunodeficiency (SCID) is a pediatric emergency because a diagnosis before live vaccines or nonirradiated blood products are given and before development of infections permits lifesaving unfractionated HLA-identical or T cell-depleted haploidentical hematopoietic stem cell transplantation, enzyme replacement therapy, or gene therapy. The need for newborn screening for this condition has been recognized for the past 15 years. However, implementation of screening required development of an assay for T-cell lymphopenia that could be performed on dried bloodspots routinely collected from newborn infants for the past 48 years. This was accomplished 6 years ago, and there have already been 7 successful pilot studies. A recommendation to add SCID to the routine newborn-screening panel was approved by the Secretary's Advisory Committee on Heritable Disorders of Newborns and Children in 2010 and was soon after approved by the Secretary of Health and Human Services. It is important for allergists, immunologists, and other health care providers to take an active role in promoting newborn screening for SCID and other T-lymphocyte abnormalities in their states. Even more important will be their roles in establishing accurate diagnoses for infants with positive screen results and in ensuring that they are given the best possible treatment.

PubMed Disclaimer

Figures

Figure 1

Absolute lymphocyte count distributions in 25 SCID and 14 Healthy Newborns at Birth. Modified from Kalman et al.(Reference 25).

Figure 2

Effect of age at time of transplantation on survival in 169 SCIDs transplanted at Duke University Medical Center from 1982-2011. Forty-nine of the infants were less than 3.5 months of age when they were given non-chemoablated transplants at Duke University Medical Center from 1982-2011.Currently all but three of the 49 (94%) are surviving for up to 29.5 years post-transplantation.

Figure 3

Cost of treatment for 74 SCID infants transplanted at Duke University Medical Center from 1998-2006, comparing costs for those who were transplanted before 3.5 months of life with the costs for those transplanted after age 3.5 months of life.

References

1. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73:147–57. - PubMed
1. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Sci. 1995;270:797–800. - PubMed
1. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20(4):394–7. - PubMed
1. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. Sci. 1996;274:97–9. - PubMed
1. Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 2001;105(2):177–86. - PubMed

The long quest for neonatal screening for severe combined immunodeficiency - PubMed (original) (raw)